Hq Spclt Pharma Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for HQ SPCLT PHARMA, and when can generic versions of HQ SPCLT PHARMA drugs launch?
HQ SPCLT PHARMA has eleven approved drugs.
There are six US patents protecting HQ SPCLT PHARMA drugs.
There are twelve patent family members on HQ SPCLT PHARMA drugs in nine countries and eighty-nine supplementary protection certificates in fifteen countries.
Summary for Hq Spclt Pharma
| International Patents: | 12 |
| US Patents: | 6 |
| Tradenames: | 14 |
| Ingredients: | 9 |
| NDAs: | 11 |
Drugs and US Patents for Hq Spclt Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hq Spclt Pharma | CALCIUM GLUCONATE IN SODIUM CHLORIDE | calcium gluconate | SOLUTION;INTRAVENOUS | 210906-003 | Jun 4, 2021 | RX | Yes | Yes | 10,342,813 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Hq Spclt Pharma | MAGNESIUM SULFATE IN PLASTIC CONTAINER | magnesium sulfate | INJECTABLE;INJECTION | 207350-003 | Dec 6, 2017 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Hq Spclt Pharma | ESMOLOL HYDROCHLORIDE | esmolol hydrochloride | INJECTABLE;INJECTION | 214172-002 | Dec 2, 2022 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Hq Spclt Pharma | TAXOL | paclitaxel | INJECTABLE;INJECTION | 020262-001 | Dec 29, 1992 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Hq Spclt Pharma | MAGNESIUM SULFATE IN PLASTIC CONTAINER | magnesium sulfate | INJECTABLE;INJECTION | 207350-002 | Dec 6, 2017 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Hq Spclt Pharma | CALCIUM GLUCONATE IN SODIUM CHLORIDE | calcium gluconate | SOLUTION;INTRAVENOUS | 210906-003 | Jun 4, 2021 | RX | Yes | Yes | 10,130,646 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Hq Spclt Pharma | LINEZOLID | linezolid | SOLUTION;INTRAVENOUS | 207001-001 | Jul 7, 2017 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Hq Spclt Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Hq Spclt Pharma | TAXOL | paclitaxel | INJECTABLE;INJECTION | 020262-001 | Dec 29, 1992 | 5,496,804 | ⤷ Try a Trial |
| Hq Spclt Pharma | CISPLATIN | cisplatin | INJECTABLE;INJECTION | 018057-004 | Nov 8, 1988 | 5,562,925 | ⤷ Try a Trial |
| Hq Spclt Pharma | CISPLATIN | cisplatin | INJECTABLE;INJECTION | 018057-004 | Nov 8, 1988 | 4,177,263 | ⤷ Try a Trial |
| Hq Spclt Pharma | PLATINOL-AQ | cisplatin | INJECTABLE;INJECTION | 018057-003 | Jul 18, 1984 | 5,562,925 | ⤷ Try a Trial |
| Hq Spclt Pharma | PLATINOL | cisplatin | INJECTABLE;INJECTION | 018057-001 | Approved Prior to Jan 1, 1982 | 4,177,263 | ⤷ Try a Trial |
| Hq Spclt Pharma | TAXOL | paclitaxel | INJECTABLE;INJECTION | 020262-001 | Dec 29, 1992 | 5,641,803 | ⤷ Try a Trial |
| Hq Spclt Pharma | PLATINOL-AQ | cisplatin | INJECTABLE;INJECTION | 018057-003 | Jul 18, 1984 | 4,310,515 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Hq Spclt Pharma Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 3429574 | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 2014143845 | ⤷ Try a Trial |
| European Patent Office | 2948379 | ⤷ Try a Trial |
| South Korea | 20150132835 | ⤷ Try a Trial |
| South Africa | 201807466 | ⤷ Try a Trial |
| Australia | 2014228155 | ⤷ Try a Trial |
| Japan | 2016515513 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Hq Spclt Pharma Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0521471 | SPC/GB03/033 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: ROSUVASTATIN OPTIONALLY IN THE FORM OF A NON-TOXIC PHARMACEUTICALLY ACCEPTABLE SALT, PARTICULARLY THE CALCIUM SALT.; REGISTERED: NL 26872 20021106; NL 26873 20021106; NL 26874 20021106; UK PL 17901/0201 20030321; UK PL 17901/0202 20030321; UK PL 17901/0203 20030321 |
| 0300652 | C300117 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: DEXMEDETOMIDINE, DESGEWENST IN DE VORM VAN EEN NIET-TOXISCH IN FARMACEUTISCH OPZICHT AANVAARDBAAR ZUURADDITIEZOUT, IN HET BIJZ ONDER DEXMEDETOMIDINE HYDROCHLORIDE; REGISTRATION NO/DATE: EU/2/02/033/001 20020830 |
| 1499331 | 122014000007 | Germany | ⤷ Try a Trial | PRODUCT NAME: NATRIUMSULFAT, MAGNESIUMSULFAT UND KALIUMSULFAT; NAT. REGISTRATION NO/DATE: 86203.00.00 20130808; FIRST REGISTRATION: BELGIEN BE434323 20130220 |
| 2957286 | 2018/046 | Ireland | ⤷ Try a Trial | PRODUCT NAME: PATIROMER SORBITEX CALCIUM; REGISTRATION NO/DATE: EU/1/17/1179 20170719 |
| 2603514 | 132019000000051 | Italy | ⤷ Try a Trial | PRODUCT NAME: COMBINAZIONE DI VABORBACTAM E/O UN SUO SALE E/O UN SUO IDRATO, E MEROPENEM, E/O UN SUO SALE E/O UN SUO IDRATO, IN PARTICOLARE MEROPENEM TRIIDRATO(VABOMERE); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/18/1334, 20181122 |
| 0961612 | C00961612/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: PACLITAXELUM-ALBUMINUM; REGISTRATION NO/DATE: SWISSMEDIC 63182 26.08.2014 |
| 1853250 | 132014902271575 | Italy | ⤷ Try a Trial | PRODUCT NAME: PACLITAXEL LEGATO ALL'ALBUMINA FORMULATO IN NANOPARTICELLE(ABRAXANE); AUTHORISATION NUMBER(S) AND DATE(S): EU/01/07/428, 20131220 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
